Sucampo to Host 2017 R&D Day on November 16 in New York
09 Novembre 2017 - 11:48PM
Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global
biopharmaceutical company, today announced that it will host its
2017 R&D Day for the investment community on Thursday, November
16, 2017 from 9:00 a.m. – 12:00 p.m. ET in New York, NY.
Sucampo will highlight its two Phase 3 rare and orphan drug
programs in Niemann-Pick Disease Type C1 (NPC-1) and Familial
Adenomatous Polyposis (FAP). Management will be joined by
three distinguished expert physicians who will present on the
significance of these rare diseases and provide perspective on
Sucampo’s development programs:
- Dr. Carol Burke – Director of the Section of
Polyposis at the Sanford R. Weiss M.D. Center for Hereditary
Colorectal Neoplasia and Vice Chair of the Gastroenterology and
Hepatology department at the Cleveland Clinic
- Dr. Paul Gissen - Head of the Genetics and
Genomic Medicine Academic Programme at the University College
London, Consultant in Inherited Metabolic Diseases at Great Ormond
Street Hospital for Children, London, UK and a Wellcome Trust
Senior Research Fellow
- Dr. Daniel Ory - Professor of Medicine, Cell
Biology and Physiology and the Alan A. And Edith L. Wolff Professor
of Cardiology at the Washington University School of Medicine
In-person attendance requires advance registration. Please note
that attendance is limited to members of the investment
community. Please email investor@sucampo.com for further
information.
A live webcast of the event will be accessible
through the Investors section of the company’s website at
http://www.sucampo.com/investors/events-presentations/. Members of
the investment community interested in joining the webcast should
log on 30 minutes before the teleconference begins to download any
software required. A replay of the webcast will also be
available and archived on the site.
About Sucampo Pharmaceuticals,
Inc.
Sucampo Pharmaceuticals, Inc. is a
biopharmaceutical company focused on the development and
commercialization of highly specialized medicines. Sucampo
has a late-stage pipeline of product candidates in clinical
development for orphan disease areas, including VTS-270, a
2-hydroxypropyl-beta-cyclodextrin product with a specific
compositional fingerprint that has been granted orphan designation
in the U.S. and Europe and is in a pivotal Phase 2b/3 clinical
trial for the treatment of Niemann-Pick Disease Type C-1, a rare
progressive genetic disorder. VTS-270 also has been granted
breakthrough therapy designation in the U.S. Sucampo has an
exclusive option for the North American rights to CPP-1x/sulindac,
which is in Phase 3 development for the treatment of familial
adenomatous polyposis and has been granted orphan drug designation
in the U.S. The company has two marketed products – AMITIZA and
RESCULA. For more information, please visit www.sucampo.com.The
Sucampo logo and the tagline, The Science of Innovation, are
registered trademarks of Sucampo AG. AMITIZA is a registered
trademark of Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow
us on LinkedIn (Sucampo Pharmaceuticals).
Twitter LinkedIn
Sucampo Forward-Looking
Statement
This press release contains "forward-looking
statements" as that term is defined in the Private Securities
Litigation Reform Act of 1995. These statements are based on
management's current expectations and involve risks and
uncertainties, which may cause results to differ materially from
those set forth in the statements. The forward-looking statements
may include statements regarding financial results, product
development, and other statements that are not historical facts.
The following factors, among others, could cause actual results to
differ from those set forth in the forward-looking statements: the
impact of pharmaceutical industry regulation and health care
legislation; Sucampo's ability to accurately predict future market
conditions; Sucampo’s ability to successfully integrate the
operations of acquired businesses; dependence on the effectiveness
of Sucampo's patents and other protections for innovative products;
the effects of competitive products on Sucampo’s products; and the
exposure to litigation and/or regulatory actions.
No forward-looking statement can be guaranteed
and actual results may differ materially from those projected.
Sucampo undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events, or otherwise. Forward-looking statements in this
press release should be evaluated together with the many
uncertainties that affect Sucampo's business, particularly those
mentioned in the risk factors and cautionary statements in
Sucampo's most recent Form 10-K as filed with the Securities and
Exchange Commission on March 8, 2017, as well as its filings with
the Securities and Exchange Commission on Forms 8-K and 10-Q since
the filing of the Form 10-K, all of which Sucampo incorporates by
reference.
Contact:Sucampo Pharmaceuticals, Inc.Silvia TaylorSenior Vice
President, Investor Relations and Corporate
Affairs1-240-223-3718staylor@sucampo.com
Grafico Azioni Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Storico
Da Giu 2023 a Giu 2024